CN105232504A - Medicine composition for treating infant recurrent respiratory tract infections - Google Patents
Medicine composition for treating infant recurrent respiratory tract infections Download PDFInfo
- Publication number
- CN105232504A CN105232504A CN201510759488.0A CN201510759488A CN105232504A CN 105232504 A CN105232504 A CN 105232504A CN 201510759488 A CN201510759488 A CN 201510759488A CN 105232504 A CN105232504 A CN 105232504A
- Authority
- CN
- China
- Prior art keywords
- respiratory tract
- compound
- pharmaceutical composition
- tract infection
- infantile respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a medicine composition for treating infant recurrent respiratory tract infections. The medicine composition comprises an effective quantity of compounds and carriers capable of being accepted in pharmacy. The structure of the compounds is shown in the specification. The compounds of the medicine composition have the remarkable effect on pathogenic bacteria causing the infant recurrent respiratory tract infections and can be developed into the novel medicine composition effective in clinic.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly.
Background technology
Infantile respiratory tract infection repeatedly is common disease in children, and they are many is caused by various pathogenic bacterium, finds that Rhodobacter capsulatus ATCC11166 is also one of pathogenic bacteria wherein in the recent period.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of infantile respiratory tract infection repeatedly, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment infantile respiratory tract infection repeatedly, and this compound has having structure:
Preferably, described infection is caused by Rhodobacter capsulatus ATCC11166.
The present invention also provides the purposes of compound in the medicine of preparation vitro inhibition Rhodobacter capsulatus ATCC11166, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or diluent.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its compositions.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, antiseptic (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, antiseptic, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogen Be very effective causing infantile respiratory tract infection repeatedly, can be developed to pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The research of the purposes of experimental example the compounds of this invention in the medicine of preparation vitro inhibition Rhodobacter capsulatus ATCC11166
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination strain Rhodobacter capsulatus ATCC11166 purchased from Bei Nuo bio tech ltd, Shanghai.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Rhodobacter capsulatus ATCC11166 is inoculated in agar plate nutritional solution plane, evenly gathers during inoculation.
Take target compound 0.01 gram, add 20000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of bacterial restrain.Measure and average for 3 times.
1.4 result
The average diameter of the bacterial restrain of Rhodobacter capsulatus ATCC11166 is 13.18mm, and this shows that target compound has the effect of extremely strong vitro inhibition Rhodobacter capsulatus ATCC11166.
Claims (9)
1. treat a compound for infantile respiratory tract infection repeatedly, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for infantile respiratory tract infection repeatedly, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizing agent or corrigent.
4. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 3, is characterized in that, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 4, is characterized in that, described diluent is lactose.
6. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment infantile respiratory tract infection repeatedly, it is characterized in that, this compound has having structure:
8. purposes according to claim 7, is characterized in that, described infection is caused by Rhodobacter capsulatus ATCC11166.
9. the purposes of compound in the medicine of preparation vitro inhibition Rhodobacter capsulatus ATCC11166, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510759488.0A CN105232504B (en) | 2015-11-10 | 2015-11-10 | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510759488.0A CN105232504B (en) | 2015-11-10 | 2015-11-10 | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105232504A true CN105232504A (en) | 2016-01-13 |
| CN105232504B CN105232504B (en) | 2016-05-18 |
Family
ID=55030507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510759488.0A Expired - Fee Related CN105232504B (en) | 2015-11-10 | 2015-11-10 | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232504B (en) |
-
2015
- 2015-11-10 CN CN201510759488.0A patent/CN105232504B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| PARRA, M. L. ET AL.: "Columnar liquid crystals based on amino-1,3,4-thiadiazole derivatives", 《LIQUID CRYSTALS》, vol. 39, no. 8, 31 December 2012 (2012-12-31), pages 917 - 925, XP001576691, DOI: doi:10.1080/02678292.2012.686635 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105232504B (en) | 2016-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis | |
| CN105111185A (en) | Pharmaceutical composition for treating vaginitis of elder people | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105254700A (en) | Medicinal composition for treatment of infection after scald | |
| CN105769899B (en) | A kind of medicine treating infantile pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tang Yan Inventor before: Xing Lili |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160421 Address after: Guan Lin Road, the First Affiliated Hospital of Henan University of Science and Technology No. 636 Luolong District 471003 in Henan city of Luoyang Province Applicant after: Tang Yan Address before: 071003 Hebei Province, Baoding City area Yonghua No. 9 North Street Applicant before: Xing Lili |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160518 Termination date: 20161110 |